|
1
|
Xiao L, He Y, Peng F, Yang J and Yuan C:
Endometrial cancer cells promote M2-Like macrophage polarization by
delivering exosomal miRNA-21 under hypoxia condition. J Immunol
Res. 2020(9731049)2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Braun MM, Overbeek-Wager EA and Grumbo RJ:
Diagnosis and management of endometrial cancer. Am Fam Physician.
93:468–474. 2016.PubMed/NCBI
|
|
3
|
Hinshaw DC and Shevde LA: The tumor
microenvironment innately modulates cancer progression. Cancer Res.
79:4557–4566. 2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Vitale I, Manic G, Coussens LM, Kroemer G
and Galluzzi L: Macrophages and metabolism in the tumor
microenvironment. Cell Metab. 30:36–50. 2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Kim J and Bae JS: Tumor-Associated
macrophages and neutrophils in tumor microenvironment. Mediators
Inflamm. 2016(6058147)2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Genin M, Clement F, Fattaccioli A, Raes M
and Michiels C: M1 and M2 macrophages derived from THP-1 cells
differentially modulate the response of cancer cells to etoposide.
BMC Cancer. 15(577)2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Cassetta L and Pollard JW:
Tumor-associated macrophages. Curr Biol. 30:R246–R248.
2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Shapouri-Moghaddam A, Mohammadian S,
Vazini H, Taghadosi M, Esmaeili SA, Mardani F, Seifi B, Mohammadi
A, Afshari JT and Sahebkar A: Macrophage plasticity, polarization,
and function in health and disease. J Cell Physiol. 233:6425–6440.
2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Cersosimo F, Lonardi S, Bernardini G,
Telfer B, Mandelli GE, Santucci A, Vermi W and Giurisato E:
Tumor-Associated macrophages in osteosarcoma: From mechanisms to
therapy. Int J Mol Sci. 21(E5207)2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Wang X, Gao S, Song L, Liu M, Sun Z and
Liu J: Astragaloside IV antagonizes M2 phenotype macrophage
polarization-evoked ovarian cancer cell malignant progression by
suppressing the HMGB1-TLR4 axis. Mol Immunol. 130:113–121.
2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Mohd Nafi SN, Siti Azrin AH, Mat Zin AA,
Othman NH and Che Jalil NA: Expression of IGFBP-rP1 in ovarian and
breast cancers in association with diabetes mellitus status. Malays
J Pathol. 41:33–39. 2019.PubMed/NCBI
|
|
12
|
Ruan W, Zhu S, Wang H, Xu F, Deng H, Ma Y
and Lai M: IGFBP-rP1, a potential molecule associated with colon
cancer differentiation. Mol Cancer. 9(281)2010.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Ma Y, Jiang J, Zhang Y, Ding Y, Xu T and
Lu B: IGFBP-rP1 acts as a potential tumor suppressor via the
suppression of ERK signaling pathway in endometrial cancer cells.
Mol Med Rep. 16:1445–1450. 2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Hu S, Chen R, Man X, Feng X, Cen J, Gu W,
He H, Li J, Chai Y and Chen Z: Function and expression of
insulin-like growth factor-binding protein 7 (IGFBP7) gene in
childhood acute myeloid leukemia. Pediatr Hematol Oncol.
28:279–287. 2011.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Ersahin T, Tuncbag N and Cetin-Atalay R:
The PI3K/AKT/mTOR interactive pathway. Mol Biosyst. 11:1946–1954.
2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Porta C, Paglino C and Mosca A: Targeting
PI3K/Akt/mTOR signaling in cancer. Front Oncol.
4(64)2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Roncolato F, Lindemann K, Willson ML,
Martyn J and Mileshkin L: PI3K/AKT/mTOR inhibitors for advanced or
recurrent endometrial cancer. Cochrane Database Syst Rev.
10(CD012160)2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Aoki M and Fujishita T: Oncogenic Roles of
the PI3K/AKT/mTOR Axis. Curr Top Microbiol Immunol. 407:153–189.
2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Komohara Y and Takeya M: CAFs and TAMs:
Maestros of the tumour microenvironment. J Pathol. 241:313–315.
2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Cortés M, Sanchez-Moral L, de Barrios O,
Fernández-Aceñero MJ, Martínez-Campanario MC, Esteve-Codina A,
Darling DS, Győrffy B, Lawrence T, Dean DC and Postigo A:
Tumor-associated macrophages (TAMs) depend on ZEB1 for their
cancer-promoting roles. EMBO J. 36:3336–3355. 2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Pan Y, Yu Y, Wang X and Zhang T:
Tumor-Associated macrophages in tumor immunity. Front Immunol.
11(583084)2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Ge Z and Ding S: The crosstalk between
tumor-associated macrophages (TAMs) and tumor cells and the
corresponding targeted therapy. Front Oncol.
10(590941)2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Cassetta L, Fragkogianni S, Sims AH,
Swierczak A, Forrester LM, Zhang H, Soong DYH, Cotechini T, Anur P,
Lin EY, et al: Human Tumor-Associated macrophage and monocyte
transcriptional landscapes reveal cancer-specific reprogramming,
biomarkers, and therapeutic targets. Cancer Cell. 35:588–602.e10.
2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Gu S, Ni T, Wang J, Liu Y, Fan Q and Wang
Y, Huang T, Chu Y, Sun X and Wang Y: CD47 blockade inhibits tumor
progression through promoting phagocytosis of tumor cells by M2
polarized macrophages in endometrial cancer. J Immunol Res.
2018(6156757)2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Giannone G, Ghisoni E, Genta S, Scotto G,
Tuninetti V, Turinetto M and Valabrega G: Immuno-Metabolism and
microenvironment in cancer: Key players for immunotherapy. Int J
Mol Sci. 21(E4414)2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Kowal J, Kornete M and Joyce JA:
Re-education of macrophages as a therapeutic strategy in cancer.
Immunotherapy. 11:677–689. 2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Damien C, Cisse F, Ligot N, Toure ML,
Konaté M, Barry SD, Saw M and Naeije G: Insights in the
pathophysiology of haemorrhagic strokes in a sub-Sahara African
country, an epidemiological and MRI study. Trop Med Int Health.
26:166–172. 2021.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Weichhart T, Hengstschläger M and Linke M:
Regulation of innate immune cell function by mTOR. Nat Rev Immunol.
15(599614)2015.PubMed/NCBI View
Article : Google Scholar
|
